Multicenter Trial of Fluoxetine as an Adjunct to Behavioral Smoking Cessation Treatment

The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers re...

Full description

Saved in:
Bibliographic Details
Published in:Journal of consulting and clinical psychology 2002-08, Vol.70 (4), p.887-896
Main Authors: Niaura, Raymond, Spring, Bonnie, Borrelli, Belinda, Hedeker, Donald, Goldstein, Michael G, Keuthen, Nancy, DePue, Judy, Kristeller, Jean, Ockene, Judy, Prochazka, Allan, Chiles, John A, Abrams, David B
Format: Article
Language:English
Subjects:
Adult
Behavior Therapy - methods
Biological and medical sciences
Cessation
Cognitive behaviour therapy
Cognitive Therapy
Combined Modality Therapy
Desintoxication. Drug withdrawal
Double-Blind Method
Drug Dosages
Drug Therapy
Female
Fluoxetine
Fluoxetine - therapeutic use
Human
Humans
Male
Medical sciences
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Serotonin Uptake Inhibitors - therapeutic use
Smoking
Smoking Cessation
Smoking Prevention
Tobacco Smoking
Treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.
ISSN:0022-006X
1939-2117
DOI:10.1037/0022-006X.70.4.887